Regen Biopharma INC 8-K filings

Regen Biopharma Inc. announced a settlement agreement resolving a lawsuit for $398,740 and the appointment of a new independent registered public accounting firm.

REGEN BIOPHARMA, INC. issued 77.8 million common shares to satisfy convertible debt principal, accrued interest, and incurred fees.

REGEN BIOPHARMA, INC. announced the issuance of over 21 million common shares to satisfy convertible debt and raise $50,000 in cash.

Regen Biopharma, Inc. announced a dividend payable in Series A Preferred Stock to shareholders of record as of February 3, 2026.

REGEN BIOPHARMA, INC. announced the issuance of 23.68 million common shares across multiple transactions in October and November 2025, raising $191,800 in cash and converting $43,740 of debt.

Regen Biopharma, Inc. is advancing its HemaXellerate therapy into a Phase I clinical trial, compensating key personnel with 40 million newly issued common shares.

Regen Biopharma, Inc. completed a series of unregistered common share sales, raising a total of $58,200 for working capital.

Regen Biopharma, Inc. entered into a securities purchase agreement for a $100,000 convertible promissory note with Labrys Fund II LP, providing $85,000 in immediate capital.

Regen Biopharma, Inc. has entered into a securities purchase agreement with CFI Capital LLC for a $130,000 convertible promissory note, providing $117,000 in immediate funding under terms highly unfavorable to existing shareholders.

Regen Biopharma, Inc. has issued 10 million common shares to its CEO, David R. Koos, to settle $50,000 of his accrued but unpaid salary, resulting in significant dilution and highlighting ongoing financial challenges.

Regen Biopharma's Board of Directors determined that previously issued financial statements for the year ended September 30, 2024, should not be relied upon due to required revisions.

Regen Biopharma, Inc. has replaced its independent auditor, appointing BCRG Group and dismissing Bush and Associates CPA LLC, effective March 31, 2025.

Regen Biopharma's unaudited financial statements for the fiscal year ended September 30, 2024, reveal a net loss of $867,252 and ongoing efforts in developing regenerative medical applications.

Regen Biopharma has declared a stock dividend of one share for every share owned, payable to shareholders of record on October 17, 2024.

Regen Biopharma has entered into a securities purchase agreement with Coventry Enterprises, securing $250,000 through a promissory note, with a portion of the funds used to repay existing debt.

Regen Biopharma has replaced its independent auditor with Bush and Associates CPA LLC, effective May 28, 2024.

Regen Biopharma has declared a share dividend of Series A Preferred Stock to all shareholders of record as of June 20, 2024, payable on or about July 1, 2024.

Regen Biopharma has dismissed its auditor, BF Borgers CPA PC, effective immediately, due to an SEC order against the firm.

Regen BioPharma has entered into an agreement for social media consulting services and amended its sublease agreement to include shared expenses.

Regen Biopharma has filed a provisional patent application for a stem cell therapy aimed at accelerating hematopoietic reconstitution.